GANX

Gain Therapeutics, Inc

A clinical-stage biotechnology company working on diseases caused by misfolded proteins, including Parkinson's disease, where its lead drug candidate GT-02287 aims to help restore a key enzyme. Founded in 2017 in Lugano, Switzerland, it uses its AI-driven Magellan platform to spot hard-to-reach spots on disease-related proteins. The name reflects the goal of "gaining" control over protein function—and access to pockets long considered undruggable.